FTC Pushes 3rd Circ. To Revive Doryx Product-Hopping Case
The Federal Trade Commission on Wednesday backed Mylan Pharmaceuticals Inc.'s bid to revive allegations that Warner Chilcott PLC tried to block generic competition for its acne medication Doryx by tweaking its...To view the full article, register now.
Already a subscriber? Click here to view full article